Ophthalmology – Open-Angle Glaucomas

Basics

Description

Open-angle glaucoma (OAG) refers to a group of chronic progressive optic neuropathies characterized by:

• Loss of retinal ganglion cells and their axons
• Characteristic optic nerve head cupping
• Retinal nerve fiber layer loss
• Corresponding visual field defects
• An anatomically open anterior chamber angle on gonioscopy

Intraocular pressure (IOP) is the most important modifiable risk factor, but glaucomatous damage can occur at either:

• Elevated IOP
• Statistically normal IOP

Classification

Open-angle glaucoma is broadly divided into:

Primary Open-Angle Glaucoma

Glaucomatous optic neuropathy with an open angle and no identifiable secondary ocular cause.

Includes:

• High-pressure primary open-angle glaucoma
• Normal-tension glaucoma

Secondary Open-Angle Glaucoma

Open-angle glaucoma caused by another ocular or systemic process.

Important examples include:

• Pseudoexfoliative glaucoma
• Pigmentary glaucoma
• Steroid-induced glaucoma
• Uveitic glaucoma
• Traumatic/angle-recession glaucoma
• Lens-related glaucoma
• Glaucoma following ocular surgery
• Elevated episcleral venous pressure
• Certain metabolic or infiltrative disorders

Ocular Hypertension

Ocular hypertension is different from glaucoma.

It consists of:

• Elevated IOP
• Open angles
• No glaucomatous optic nerve damage
• No corresponding visual field loss

It is a risk state for future glaucoma rather than established optic neuropathy.

Epidemiology

Glaucoma is one of the leading causes of irreversible blindness worldwide.

Primary open-angle glaucoma becomes increasingly common with:

• Increasing age
• Family history
• African ancestry
• Certain genetic backgrounds

A large proportion of affected individuals remain undiagnosed because early disease is usually asymptomatic.

Risk Factors

Important risk factors for developing or progressing open-angle glaucoma include:

• Elevated IOP
• Increasing age
• Family history of glaucoma
• African ancestry
• Thin central corneal thickness
• Myopia
• Large vertical cup-to-disc ratio
• Disc hemorrhage
• Lower ocular perfusion pressure
• Greater baseline structural or visual field damage

Possible systemic associations include:

• Migraine
• Vascular dysregulation
• Sleep apnea
• Systemic hypotension

These associations are particularly discussed in normal-tension glaucoma.

Genetics

Primary open-angle glaucoma is genetically heterogeneous.

Genes associated with selected forms include:

• MYOC
• OPTN
• TBK1
• Multiple polygenic risk loci

Most adult POAG is multifactorial rather than attributable to a single gene mutation.

Genetic testing is not routinely required in typical adult-onset disease.

Pathophysiology

The final common pathway is:

Retinal ganglion cell death → axonal loss → optic nerve cupping → visual field loss

Major mechanisms include:

• Mechanical stress at the lamina cribrosa
• Impaired axoplasmic transport
• Ischemia and vascular dysregulation
• Mitochondrial dysfunction
• Oxidative stress
• Neuroinflammation

Role of Intraocular Pressure

IOP is the most important treatable risk factor.

Damage may occur because of:

• Absolute pressure elevation
• Pressure fluctuations
• Individual susceptibility of the optic nerve

A “normal” IOP does not guarantee protection from glaucoma.

Conversely, some patients tolerate elevated IOP for years without developing damage.

Aqueous Humor Dynamics

IOP depends on the balance between:

• Aqueous humor production by the ciliary body
• Trabecular outflow
• Uveoscleral outflow
• Episcleral venous pressure

Most OAG therapies work by:

• Decreasing aqueous production
• Increasing trabecular outflow
• Increasing uveoscleral outflow

Diagnosis

Diagnosis requires integration of:

• IOP
• Gonioscopy
• Optic nerve appearance
• OCT
• Visual field testing
• Central corneal thickness
• Longitudinal change

The diagnosis should not be based on IOP alone.

History

Ask about:

• Family history of glaucoma
• Previous elevated IOP
• Steroid exposure
• Ocular trauma
• Uveitis
• Previous ocular surgery
• Migraine
• Sleep apnea
• Systemic hypotension
• Vascular disease
• Medication adherence
• Previous laser or glaucoma surgery

Symptoms

Early POAG is typically:

Asymptomatic

Central visual acuity usually remains good until advanced disease.

Late symptoms may include:

• Peripheral field loss
• Difficulty with contrast
• Trouble navigating in dim light
• Reading difficulty from paracentral loss
• Advanced tunnel vision

Visual Acuity

Visual acuity may remain normal until late disease.

Reduced central vision early in the course should raise concern for:

• Macular disease
• Optic neuropathy
• Advanced central glaucomatous damage
• Another diagnosis

Pupillary Examination

A relative afferent pupillary defect may occur when glaucoma is:

• Markedly asymmetric
• Advanced in one eye

Gonioscopy

Gonioscopy is mandatory in the evaluation of glaucoma.

Open-angle glaucoma requires visualization of the trabecular meshwork.

Gonioscopy also helps detect secondary causes such as:

• Pigment deposition
• Pseudoexfoliation
• Angle recession
• Neovascularization
• Peripheral anterior synechiae
• Inflammatory debris

Central Corneal Thickness

Pachymetry should be obtained because CCT influences:

• IOP interpretation
• Risk stratification

Thin corneas may underestimate IOP and are associated with greater glaucoma risk.

There is no universally accepted formula to “correct” IOP numerically for CCT.

Optic Nerve Examination

A dilated stereoscopic optic nerve examination should evaluate:

• Cup-to-disc ratio
• Vertical cupping
• Neuroretinal rim thickness
• Focal notching
• Inter-eye asymmetry
• Disc hemorrhage
• Pallor
• RNFL defects

Characteristic Glaucomatous Optic Nerve Findings

Typical findings include:

• Progressive cup enlargement
• Inferotemporal rim thinning
• Superotemporal rim thinning
• Vertical elongation of the cup
• Focal rim notch
• Laminar dot sign
• Acquired optic nerve pit
• Corresponding RNFL wedge defect

ISNT Rule

In many normal optic nerves, rim thickness follows approximately:

Inferior > Superior > Nasal > Temporal

Violation of this pattern can raise suspicion for glaucoma.

However, the ISNT rule is not sufficiently specific to diagnose glaucoma by itself.

Disc Hemorrhage

A splinter or flame-shaped hemorrhage at the disc margin is an important sign.

It is associated with:

• Higher risk of progression
• Localized RNFL loss
• Normal-tension glaucoma in particular

A new disc hemorrhage should prompt reassessment of:

• Target IOP
• Adherence
• Progression rate

Optic Disc Pallor

Glaucoma usually produces:

Cupping greater than pallor

If optic disc pallor is excessive relative to cupping, consider:

• Ischemic optic neuropathy
• Compressive optic neuropathy
• Toxic/nutritional optic neuropathy
• Hereditary optic neuropathy
• Prior optic neuritis

Optical Coherence Tomography

OCT is central to modern glaucoma diagnosis and follow-up.

It evaluates:

• Peripapillary RNFL
• Macular ganglion cell complex
• Ganglion cell–inner plexiform layer
• Optic nerve head

Structural Progression

Serial OCT can detect:

• Progressive RNFL thinning
• Ganglion cell loss
• Focal structural change

Structural progression may precede detectable visual field loss.

Preperimetric Glaucoma

Some patients have clear structural glaucomatous damage with:

• Normal standard automated perimetry

This is called:

Preperimetric glaucoma

Thus, a normal visual field does not exclude early glaucoma.

Visual Field Testing

Standard automated perimetry is used to detect functional damage.

Typical glaucomatous defects include:

• Paracentral scotoma
• Nasal step
• Arcuate scotoma
• Seidel scotoma
• Temporal wedge
• Advanced generalized constriction

Structure-Function Correlation

Glaucomatous field defects should correspond anatomically to optic nerve and RNFL damage.

For example:

• Superior RNFL loss → inferior visual field defect
• Inferior RNFL loss → superior visual field defect

Poor correlation should raise suspicion for another optic neuropathy.

Central Visual Field Testing

A 10-2 field is useful when there is:

• Paracentral damage
• Fixation-threatening disease
• Advanced glaucoma

A 24-2C strategy may also improve central sampling.

Optic Disc Photography

Baseline and serial optic disc photographs remain valuable because they can document:

• Progressive rim loss
• Disc hemorrhage
• Cup enlargement
• RNFL changes

They complement OCT rather than being replaced by it.

IOP Measurement

Goldmann applanation tonometry remains the clinical reference standard.

Important considerations include:

• Time of day
• CCT
• Corneal biomechanics
• Measurement technique
• IOP fluctuation

Repeated measurements may be useful in selected patients.

Diurnal IOP Variation

Some patients have clinically important pressure peaks outside routine office hours.

Consider repeated measurements when:

• Progression occurs despite apparently low office IOP
• IOP variability is suspected
• Normal-tension glaucoma is being evaluated

Differential Diagnosis

Open-angle glaucoma is a diagnosis of exclusion.

Important mimics include:

• Physiologic large cupping
• High myopia
• Congenital optic disc anomalies
• Optic nerve coloboma
• Tilted disc
• Optic nerve pits
• Dominant optic atrophy
• Ischemic optic neuropathy
• Compressive optic neuropathy
• Toxic/nutritional optic neuropathy
• Optic neuritis
• Prior papilledema

Neuroimaging Red Flags

Consider neuroimaging when there is:

• Pallor greater than cupping
• Marked visual acuity loss
• Central scotoma inconsistent with glaucoma
• Color vision loss out of proportion
• Rapid progression
• Severe unilateral disease
• Hemianopic visual field defect
• Neurologic symptoms

Treatment Principles

The established treatment goal is:

Lower IOP sufficiently to slow progression and preserve useful lifetime vision.

The target IOP is individualized according to:

• Baseline IOP
• Disease severity
• Rate of progression
• Age
• Life expectancy
• Central visual field involvement
• Fellow-eye status

Target IOP

There is no single safe IOP for every patient.

A commonly used initial framework is:

Mild glaucoma

Approximately 20–30% reduction from baseline

Moderate glaucoma

Often 30% or more

Advanced glaucoma

May require very low target pressures

Targets should be revised according to actual progression.

First-Line Treatment Options

Modern initial treatment commonly includes:

• Selective laser trabeculoplasty
• Prostaglandin analog
• Sometimes both

Choice depends on:

• Disease severity
• Patient preference
• Adherence
• Cost
• Ocular surface disease
• Expected treatment burden

Selective Laser Trabeculoplasty

SLT lowers IOP by improving trabecular outflow.

Advantages include:

• Effective IOP reduction
• No daily medication adherence
• Minimal systemic effects
• Can be repeated in selected patients

SLT is now widely accepted as:

A first-line treatment option for primary open-angle glaucoma and ocular hypertension

rather than merely an adjunct after medications fail.

Prostaglandin Analogs

Examples include:

• Latanoprost
• Travoprost
• Bimatoprost
• Tafluprost
• Latanoprostene bunod

They primarily increase uveoscleral and/or trabecular outflow.

Advantages:

• Strong IOP lowering
• Once-daily dosing
• Minimal systemic effects

Prostaglandin Adverse Effects

Possible adverse effects include:

• Conjunctival hyperemia
• Eyelash growth
• Periocular skin pigmentation
• Iris darkening
• Prostaglandin-associated periorbitopathy

Beta-Blockers

Examples:

• Timolol
• Betaxolol

They lower IOP by reducing aqueous production.

Use cautiously in:

• Asthma
• COPD
• Bradycardia
• Heart block
• Symptomatic hypotension

Alpha-2 Agonists

Example:

• Brimonidine

Mechanisms include:

• Reduced aqueous production
• Increased uveoscleral outflow

Adverse effects include:

• Follicular allergy
• Dry mouth
• Fatigue
• Somnolence

Topical Carbonic Anhydrase Inhibitors

Examples:

• Dorzolamide
• Brinzolamide

They reduce aqueous production.

Often used as:

• Adjunctive therapy
• Combination therapy

Rho Kinase Inhibitors

Examples include:

• Netarsudil

They primarily improve trabecular outflow and may also reduce episcleral venous pressure.

Adverse effects include:

• Conjunctival hyperemia
• Corneal verticillata
• Subconjunctival hemorrhage

Cholinergic Agents

Pilocarpine increases trabecular outflow by contracting the ciliary muscle.

It is used far less often in chronic OAG because of:

• Brow ache
• Miosis
• Induced myopia
• Reduced night vision
• Retinal detachment concern in susceptible patients

Oral Carbonic Anhydrase Inhibitors

Examples:

• Acetazolamide
• Methazolamide

These may be used temporarily when rapid IOP reduction is required.

They are generally unsuitable for routine long-term therapy because of systemic adverse effects.

Medication Adherence

Adherence is a major determinant of treatment success.

Barriers include:

• Cost
• Complex regimens
• Ocular surface irritation
• Forgetfulness
• Poor understanding
• Difficulty instilling drops

Simplifying therapy can improve adherence.

Laser Trabeculoplasty

SLT has largely replaced argon laser trabeculoplasty in routine practice because it:

• Uses lower energy
• Causes less thermal damage
• Can be repeated more readily

Cataract Surgery

Phacoemulsification alone may modestly reduce IOP in some patients with open-angle glaucoma.

It is not usually sufficient treatment for advanced disease.

Minimally Invasive Glaucoma Surgery

MIGS procedures are increasingly used for:

• Mild to moderate glaucoma
• Reducing medication burden
• Combination with cataract surgery

Examples include:

• Trabecular micro-bypass stents
• Goniotomy
• Trabeculotomy
• Canal-based procedures

Limitations of MIGS

MIGS generally provides:

• Modest to moderate IOP reduction
• Lower complication rates than trabeculectomy

However, many MIGS procedures cannot reliably achieve the very low pressures required for:

• Advanced glaucoma
• Rapid progression
• Severe fixation-threatening disease

Trabeculectomy

Trabeculectomy remains one of the most effective methods for achieving:

Very low IOP

It is especially useful for:

• Advanced glaucoma
• Rapid progression
• Failure of medical/laser therapy

Trabeculectomy Complications

Potential complications include:

• Hypotony
• Shallow anterior chamber
• Choroidal effusion
• Blebitis
• Endophthalmitis
• Cataract progression
• Bleb failure

Glaucoma Drainage Devices

Tube shunts include:

• Ahmed
• Baerveldt
• Other drainage implants

They are particularly useful when:

• Trabeculectomy has failed
• Conjunctival scarring is present
• Secondary glaucoma exists
• Prior ocular surgery complicates filtration surgery

Cyclophotocoagulation

Cyclodestructive procedures reduce aqueous production by treating the ciliary body.

Modern approaches include:

• Transscleral cyclophotocoagulation
• Micropulse cyclophotocoagulation
• Endoscopic cyclophotocoagulation

They are increasingly used beyond blind painful eyes, but patient selection remains important.

Major Evidence From Clinical Trials

Several major studies established that lowering IOP reduces glaucoma risk and progression.

OHTS

The Ocular Hypertension Treatment Study showed that treating ocular hypertension reduced conversion to POAG.

At about 5 years:

• Untreated: ~9.5% developed glaucoma
• Treated: ~4.4%

Collaborative Normal-Tension Glaucoma Study

Approximately:

30% IOP reduction

significantly reduced progression in normal-tension glaucoma.

Early Manifest Glaucoma Trial

The EMGT demonstrated that:

Each additional mmHg of IOP reduction lowers the risk of progression

and confirmed the importance of pressure reduction even in relatively early glaucoma.

LiGHT Trial

The LiGHT trial supported:

SLT as an effective first-line treatment

for many patients with newly diagnosed open-angle glaucoma or ocular hypertension.

Many patients were able to remain drop-free for substantial periods.

Neuroprotection

Glaucoma is a neurodegenerative disease, and many direct neuroprotective strategies have been studied.

However:

No medication has yet been definitively proven to provide clinically meaningful neuroprotection independent of IOP lowering.

IOP reduction remains the only established treatment proven to slow progression.

Follow-Up

Follow-up frequency depends on:

• Disease severity
• Target IOP
• Progression rate
• Treatment changes
• Adherence

Mild Stable Disease

May often be monitored every:

4–6 months

with periodic:

• OCT
• Visual field testing
• Disc examination

Moderate or Advanced Disease

Often requires closer follow-up:

Every 2–4 months

depending on stability.

After Treatment Changes

Patients should be reassessed after:

• Starting new medication
• SLT
• Incisional surgery
• Significant IOP change

to confirm:

• Efficacy
• Safety
• Adherence

Rate of Progression

The key question in long-term management is:

How fast is the patient losing retinal ganglion cells and visual field?

Management should be intensified when progression threatens useful lifetime vision.

Patient Education

Patients should understand that:

• Glaucoma is usually asymptomatic until late.
• Vision already lost cannot currently be restored.
• Treatment aims to prevent further damage.
• Adherence and follow-up are essential.
• “Normal” IOP does not necessarily mean glaucoma is controlled.

Prognosis

Prognosis depends on:

• Disease severity at diagnosis
• Age
• Life expectancy
• Baseline IOP
• Rate of progression
• Central field involvement
• Treatment adherence
• Ability to achieve target IOP

Early diagnosis and appropriate treatment greatly reduce the risk of severe visual loss.

Complications

Uncontrolled open-angle glaucoma can lead to:

• Progressive RNFL loss
• Progressive visual field loss
• Paracentral scotoma
• Severe peripheral field constriction
• Loss of fixation
• Permanent visual impairment
• Blindness

Treatment complications may include:

• Ocular surface disease
• Medication intolerance
• Laser-related IOP spikes
• Hypotony
• Infection
• Surgical failure

Ophthalmology Pearls

• Open-angle glaucoma = characteristic glaucomatous optic neuropathy with an open angle on gonioscopy.
• IOP is the most important modifiable risk factor, but glaucoma can occur at statistically normal pressures.
• Diagnosis is based on optic nerve/RNFL damage and corresponding functional loss, not IOP alone.
• Gonioscopy is essential to distinguish open-angle from angle-closure and secondary mechanisms.
• Typical optic nerve findings include vertical cupping, focal rim notching, RNFL loss, and disc hemorrhage.
• Disc pallor greater than cupping suggests a nonglaucomatous optic neuropathy.
• OCT may detect structural loss before standard visual fields become abnormal—preperimetric glaucoma.
• Glaucomatous visual field defects should anatomically correspond to RNFL and disc damage.
• SLT and prostaglandin analogs are both appropriate first-line treatments in many patients.
• MIGS is useful mainly for mild to moderate disease and medication reduction; it may not achieve sufficiently low IOP for advanced glaucoma.
• Trabeculectomy remains one of the most effective procedures when a very low target IOP is required.
• Major trials consistently show that lowering IOP reduces the risk of glaucoma development and progression.
• No independent neuroprotective therapy has yet replaced IOP lowering as the evidence-based foundation of glaucoma treatment.